Baxdrostat lowers 24-hour SBP in resistant hypertension trial

ClinicalTrials.gov posted results on 2026-08-06 for baxdrostat in resistant hypertension. In this completed phase 3 study, the drug lowered ambulatory 24-hour systolic blood pressure more than placebo, with a least-squares mean difference of -14.0 mmHg.

Background

The trial evaluated baxdrostat in participants with resistant hypertension. The posted record describes a multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 mg orally once daily versus placebo.

Trial design

The study enrolled 218 participants and assessed changes in average 24-hour ambulatory blood pressure at week 12. The record also included seated systolic blood pressure, daytime and nighttime ambulatory systolic blood pressure, ambulatory diastolic blood pressure, and the proportion of participants reaching an ambulatory 24-hour average SBP below 130 mmHg.

Key results

For ambulatory 24-hour average SBP at week 12, baxdrostat was associated with a least-squares mean change of -16.6 mmHg versus -2.6 mmHg with placebo. The posted ANCOVA analysis reported a placebo-adjusted least-squares mean difference of -14.0 mmHg (95% CI, -17.2 to -10.8; p=0.0001).

Other posted blood-pressure measures also favored baxdrostat: nighttime SBP changed by -16.0 mmHg versus -2.1 mmHg, daytime SBP by -16.8 mmHg versus -2.7 mmHg, seated SBP by -14.9 mmHg versus -4.7 mmHg, and ambulatory 24-hour DBP by -8.3 mmHg versus -1.5 mmHg. More participants reached ambulatory 24-hour average SBP below 130 mmHg with baxdrostat than placebo, 60 versus 14.

The analysis section also listed additional placebo-adjusted least-squares mean differences of -13.9 mmHg, -14.1 mmHg, -10.3 mmHg, and -6.8 mmHg, each with p=0.0001, and an odds ratio of 15.2 (95% CI, 6.6 to 35.2) for a binary outcome in the record.

What this means

These posted results suggest baxdrostat produced a clinically meaningful reduction in ambulatory blood pressure in a hard-to-control hypertension population. Because the trial was placebo-controlled and blinded, the findings add weight to the blood-pressure effect seen in the record, although the posted data do not include adverse-event details here.

Source

This information is based on ClinicalTrials.gov trial results for NCT06168409 posted on 2026-08-06. The record is available at clinicaltrials.gov.